Regeneron Pharmaceuticals Earnings: REGN Stock Rockets 7% on Q3 Beat

Regeneron Pharmaceuticals (NASDAQ:REGN) earnings for the biotechnology company’s third quarter of 2019 have REGN stock soaring on Tuesday. This is thanks to its adjusted EPS of $6.67 on revenue of $2.05 billion. These both easily beat out Wall Street’s estimates of $6.36 per share and $1.99 billion for the period.